Tyra Biosciences (NASDAQ:TYRA) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of Tyra Biosciences (NASDAQ:TYRA) from a sell rating to a hold rating in a research note published on Saturday.

Other research analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Friday, August 22nd. Raymond James Financial assumed coverage on Tyra Biosciences in a report on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 price target on the stock. Piper Sandler assumed coverage on Tyra Biosciences in a report on Wednesday, May 21st. They set an “overweight” rating and a $33.00 price target on the stock. Finally, Oppenheimer reiterated an “outperform” rating and set a $36.00 price target on shares of Tyra Biosciences in a report on Wednesday, September 10th. One analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. Based on data from MarketBeat.com, Tyra Biosciences presently has a consensus rating of “Buy” and a consensus price target of $31.86.

Tyra Biosciences Stock Performance

Shares of TYRA stock opened at $12.31 on Friday. The stock’s fifty day moving average is $11.24 and its two-hundred day moving average is $10.26. The firm has a market capitalization of $656.12 million, a P/E ratio of -6.92 and a beta of 1.09. Tyra Biosciences has a fifty-two week low of $6.42 and a fifty-two week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.06. On average, equities analysts forecast that Tyra Biosciences will post -1.57 earnings per share for the current year.

Insider Activity

In related news, Director Gilla Kaplan sold 9,568 shares of the firm’s stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $9.78, for a total transaction of $93,575.04. Following the completion of the sale, the director directly owned 28,231 shares of the company’s stock, valued at approximately $276,099.18. This trade represents a 25.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 15.20% of the company’s stock.

Institutional Trading of Tyra Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. HighVista Strategies LLC increased its position in shares of Tyra Biosciences by 4.3% during the 2nd quarter. HighVista Strategies LLC now owns 24,962 shares of the company’s stock worth $239,000 after purchasing an additional 1,021 shares during the last quarter. American Century Companies Inc. increased its stake in Tyra Biosciences by 5.8% during the first quarter. American Century Companies Inc. now owns 23,431 shares of the company’s stock worth $218,000 after purchasing an additional 1,289 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Tyra Biosciences by 14.5% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after purchasing an additional 1,668 shares during the period. US Bancorp DE increased its stake in Tyra Biosciences by 50.5% during the first quarter. US Bancorp DE now owns 5,435 shares of the company’s stock worth $51,000 after purchasing an additional 1,823 shares during the period. Finally, Rhumbline Advisers increased its stake in Tyra Biosciences by 7.2% during the first quarter. Rhumbline Advisers now owns 28,081 shares of the company’s stock worth $261,000 after purchasing an additional 1,879 shares during the period. 84.14% of the stock is owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.